Dibra S.p.a.

Bracco International Bv

Bracco Imaging S.p.a.

Euticals Spa

Amri Italy S.r.l.

Other

Flamma S.p.a.

Curia IP Holdings, LLC

Prime European Therapeucials S.p.a.

Maria Argese

Giorgio Ripa

Paride Grisenti

Vittorio Valle

Giuseppe Motta

Alessandro Scala

Maria Donata Grilli

Emanuela Fumagalli

Daniele Pengo

Giuseppe Guazzi

Luciano Lattuada

Pier Lucio Anelli

Valeria Boi

Sonia Gazzetto

Laura Galimberti

Giuseppe Manfredi

Fulvia Vella

Livio Cavalieri

Fabrizio Rebasti

Massimo Verzini

Marino Brocchetta

Marcella Murru

Federico Maisano

Enrico Moretti

Giovanni Rivolta

Renato Geremia

Wei He

Leila Vahdati

Mario Scotti

Daniela Comi

Francesco Chiesa

Paolo Cremonesi

Laura Alessandroni

Patrizia Ambrosetti

Paolo Anesa

Alberto Varalli

Alessandro Livieri

Roberto Scrocchi

Elahi Shahrzad Reza

Livio Cavaliere

The present invention relates to a process for the purification of (R)-2-amino-3-phenylpropyl carbamate in perspective of the subsequent conversion in the corresponding HCl salt (SOLRIAMFETOL). The invention further relates to the process for preparing a batch of purified solriamfetol, as well as to the purified (R)-2-amino-3-phenylpropyl carbamate or its hydrochloride salt.

Process for the purification of (R)-2-amino-3-phenylpropyl carbamate

A Rifaximin polymorphic mixture of &#x3b1;/&#x3b2; form in a relative ratio of 85/15&#xb1;3 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of &#x3b1;/&#x3b2; form in a relative ratio of 85/15&#xb1;3.

Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations

Polymorphic mixture of rifaximin and its use for the preparation of solid formulations

The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chlorosulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.

Process for the preparation of a sulfated derivative of 3,5-diiodo-o-[3-iodophenyl]-l-tyrosine

A process for the preparation of the amorphous form of Regadenoson of formula is disclosed together with new crystalline polymorphic forms E, F and G and methods for their preparation. Regadenoson amorphous form can be prepared in mild reaction conditions with high chemical purity (&#x3e;99.6%) and high stability to the heating. A particularly thermodynamically stable anhydrous crystalline form of Regadenoson (form G) is also disclosed, provided with high stability not when exposed to 90% RH at 25&#xb0; C. for 96 hour, but also to the heating up to 200&#xb0; C.

Stable solid forms of regadenoson

The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chloro-sulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.

Process for the preparation of a sulfated derivative of 3,5-diiodo-O-[3-iodophenyl]-L-tyrosine

A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endothermic event at about 191-193&#xb0; C. determined by DSC. A process for the preparation of the cocrystal is also disclosed. Preferably, the cocrystal has a particle size distribution of D90&#x3c;10 &#x3bc;m. The cocrystal is also disclosed for use as medicament, in particular for the treatment of a respiratory complaint, such as chronic obstructive pulmonary disease (COPD), bronchitis, emphysema and asthma. A pharmaceutical composition comprising the cocrystal as active ingredient is also disclosed, in particular for administration by inhalation. In the latter case, said cocrystal has a mean particle size of 0.5 to 10 &#x3bc;m, preferably 1 to 6 &#x3bc;m, more preferably 1.5 to 5 &#x3bc;m.

Crystalline form of tiotropium bromide with lactose

Disclosed is the preparation of 2-deoxy-D-erythro-2,2-difluoro-ribofuranose-3,5-dibenzoate, a known intermediate for the preparation of Gemcitabine, by means of a reduction process; further disclosed is the purification of Gemcitabine by chromatography and the purification of Gemcitabine hydrochloride by crystallization techniques from ternary solvent mixtures. The main advantage of the invention is providing Gemcitabine hydrochloride with purity in conformity with the Pharmacopoeia requirements, as well as a process particularly convenient from the industrial point of view.

Process for the preparation of gemcitabine hydrochloride

A process for the preparation of compound of formula (I A), decahydro-2a,4a,6a,8a-tetraazacyclopent[fg]accnaphthylene and the corresponding functionalized compounds of general formula (I), intermediates for the preparation of 1,4,7,10-tetraazacyclododecane (II A) and corresponding derivatives (II), by preparation of compounds of general formula (III) and subsequent reduction thereof.

Process for the preparation of decahydro-2a,4a,6a,8a-tetraazacyclopent[fg]acenaphthylene and functionalized derivatives

1,4,7,10-Tetraazacyclodecane, a precursor for the synthesis of macrocylic chelating agents for metal ions such as gadolinium, is prepared efficiently as a highly pure product on an industrial scale.

Process for the preparation of 1,4,7,10-tetraazacyclododecane

A novel process for the preparation of N,N&prime;-bis&lsqb;2,3-dihydroxypropyl&rsqb;-5-&lsqb;(hydroxyacetyl) methylamino&rsqb;-2,4,6-triiodo-1, 3-benzenedi carboxamide of formula (I), commonly known as lomeprol, a novel non-ionic contrast agent which shows very good safety and contrast effectiveness.

Process for the preparation of n,n'-bis&lsqb;2,3-dihydroxypropyl&rsqb;-5-&lsqb;(hydroxyacetyl) methylamino&rsqb;-2, 4,6-triiodo-1, 3-benzenedi carboxamide

The present invention relates to the novel compound, 1,4,7,10-tetraazabicyclo[8.2.2]tetradecan-2-one of formula (I), its preparation and the use thereof for the preparation of tetraazamacrocycles . ##STR1##

Process of preparing tetraacetic acid derivatives

Growing community of inventors

Sedriano, Italy

Maria Argese